Prioritizing treatments in type 2 diabetes mellitus

Archives of Internal Medicine

Volumn 172, Issue 10, 2012, Pages 770-772

  Margolis, Karen L ^a   O'Connor, Patrick J ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

BLOOD GLUCOSE MONITORING; COMORBIDITY; DRUG MECHANISM; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE;

EID: 84861680004     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.1775     Document Type: Note

References (11)

1. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2012;172(10):761-769.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
3. Holman RR, Paul SK, Bethel MA,Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577- 1589.
4. Gerstein HC, Miller ME, Genuth S, et al ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
5. Patel A, MacMahon S, Chalmers J, et alADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. (Pubitemid 351831357)
6. Hansen MB, Jensen ML, Carstensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012;55(2):294-302.
7. HuangES,BrownSE,EwigmanBG,FoleyEC,MeltzerDO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30(10):2478-2483. (Pubitemid 47547775)
8. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med. 2010;170(12):1037-1044.
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591. (Pubitemid 351214285)
10. Patel A, MacMahon S, Chalmers J, et al ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840. (Pubitemid 47362321)
11. Doria A, Wojcik J, Xu R, et al. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA. 2008;300(20):2389-2397.